Cancer research firm Champions Oncology's Q2 revenue rises as bookings quality improves

Reuters2025-12-16

Cancer research firm <a href="https://laohu8.com/S/CSBR">Champions Oncology</a>'s <a href="https://laohu8.com/S/QTWO">Q2</a> revenue rises as bookings quality improves

Overview

Translational oncology research firm's fiscal Q2 revenue rose 11% yr/yr to $15 mln
Company reported net income of $237,000 for fiscal Q2

Outlook

Company expects positive adjusted EBITDA for the full fiscal year
Champions Oncology anticipates year-over-year revenue growth

Result Drivers

BOOKINGS QUALITY - Improved bookings quality contributed to higher revenue conversion and growth
OPERATIONAL EFFICIENCIES - Oncology services margin improved to 52% due to operational efficiencies and stable costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue	Beat	$15 mln	$14.04 mln (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 78.6% above its December 12 closing price of $6.72

Press Release: ID:nACSrwr9Xa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591624878?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 05:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591624878","market":"us","top_or_hot":-1,"title":"Cancer research firm Champions Oncology's Q2 revenue rises as bookings quality improves","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer research firm <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a>'s <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue rises as bookings quality improves</title></head><body><p><span>Overview</span></p><ul><li><p>Translational oncology research firm's fiscal Q2 revenue rose 11% yr/yr to $15 mln</p></li><li><p>Company reported net income of $237,000 for fiscal Q2</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects positive adjusted EBITDA for the full fiscal year</p></li><li><p>Champions Oncology anticipates year-over-year revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BOOKINGS QUALITY - Improved bookings quality contributed to higher revenue conversion and growth</p></li><li><p>OPERATIONAL EFFICIENCIES - Oncology services margin improved to 52% due to operational efficiencies and stable costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$15 mln</p></td><td><p>$14.04 mln (1 Analyst)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 78.6% above its December 12 closing price of $6.72</p></li></ul><p>Press Release: <span>ID:nACSrwr9Xa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer research firm Champions Oncology's Q2 revenue rises as bookings quality improves</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer research firm Champions Oncology's Q2 revenue rises as bookings quality improves\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 05:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer research firm <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a>'s <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue rises as bookings quality improves</title></head><body><p><span>Overview</span></p><ul><li><p>Translational oncology research firm's fiscal Q2 revenue rose 11% yr/yr to $15 mln</p></li><li><p>Company reported net income of $237,000 for fiscal Q2</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects positive adjusted EBITDA for the full fiscal year</p></li><li><p>Champions Oncology anticipates year-over-year revenue growth</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BOOKINGS QUALITY - Improved bookings quality contributed to higher revenue conversion and growth</p></li><li><p>OPERATIONAL EFFICIENCIES - Oncology services margin improved to 52% due to operational efficiencies and stable costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td><p>Beat</p></td><td><p>$15 mln</p></td><td><p>$14.04 mln (1 Analyst)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 78.6% above its December 12 closing price of $6.72</p></li></ul><p>Press Release: <span>ID:nACSrwr9Xa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL1N3XL0X4:1","article_id":"2591624878","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591624878","pubTimestamp":1765833126,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer research firm Champions Oncology's Q2 revenue rises as bookings quality improvesOverviewTranslational oncology research firm's fiscal Q2 revenue rose 11% yr/yr to $15 mlnCompany reported net in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","CSBR":"Champions Oncology, Inc."},"translate_title":"随着预订质量的提高，癌症研究公司Champions Oncology第二季度收入增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSBR":0.9},"content_text":"Cancer research firm Champions Oncology's Q2 revenue rises as bookings quality improvesOverviewTranslational oncology research firm's fiscal Q2 revenue rose 11% yr/yr to $15 mlnCompany reported net income of $237,000 for fiscal Q2OutlookCompany expects positive adjusted EBITDA for the full fiscal yearChampions Oncology anticipates year-over-year revenue growthResult DriversBOOKINGS QUALITY - Improved bookings quality contributed to higher revenue conversion and growthOPERATIONAL EFFICIENCIES - Oncology services margin improved to 52% due to operational efficiencies and stable costsKey DetailsMetricBeat/MissActualConsensus EstimateQ2 RevenueBeat$15 mln$14.04 mln (1 Analyst)Analyst CoverageThe one available analyst rating on the shares is \"buy\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 78.6% above its December 12 closing price of $6.72Press Release: ID:nACSrwr9XaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591624878","isCrawlerRequest":true}